SMN2 antisense oligonucleotide exon 7 inclusion therapy (SNA, spinal muscular atrophy/Huntington disease) (Exicure)

N/A

Report date: 2025/01/26 16:13:17
NME

Base Information

Drug NameSMN2 antisense oligonucleotide exon 7 inclusion therapy (SNA, spinal muscular atrophy/Huntington disease) (Exicure)
Drug Alias Namespherical nucleic acids (Exicure)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionSMN2 gene modulatorsNeuroprotectants
TargetsUpdating
Therapy Area/IndicationsMuscular Atrophy, SpinalHuntington Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesExicure Inc
China Registration ClassN/A

Develop Information

Active CompaniesExicure Inc
Inactive CompaniesN/A
Active IndicationsMuscular Atrophy, SpinalHuntington Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A